Evidence map›Paper›PMID 42602443›Full record

ArticleJHLT open2026

Extended static preservation of donor lungs at 10°C and early post-transplant outcomes: Experience from a center in the US.

Yub Raj Sedhai, Christopher S King, Silpa D Kilaru, Zein Kattih, Adriana Kochi, Vikramjit Khangoora, Jared D Wilkinson, Alan S Nyquist, Anju Singhal, Junad M Chowdhury and 5 more

Abstract read
In one paragraph

Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yub Raj SedhaiAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Christopher S KingAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Silpa D KilaruAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Zein KattihAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Adriana KochiAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Vikramjit KhangooraAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Jared D WilkinsonAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Alan S NyquistAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Anju SinghalAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Junad M ChowdhuryAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Christopher A ThomasAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Oksana A ShlobinAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Steven D NathanAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Daniel TangDivision of Cardiothoracic Surgery, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.
Shambhu AryalAdvanced Lung Disease and Transplant Program, Inova Schar Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, Virginia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: An emerging body of evidence suggests that extended static preservation of donor lung allografts at 10°C yields clinical outcomes comparable to standard storage, while enabling transplantation to be performed in a semi-elective manner. We conducted a retrospective analysis to determine whether a mid-sized lung transplant program could replicate outcomes reported in a recent clinical trial and larger transplant centers, while assessing the feasibility and real-world applicability of extended static cold storage. Methods: We conducted a retrospective single-center study of lung transplants performed between January 1 and December 31, 2025. Recipients were categorized by preservation strategy into standard storage or extended static cold storage at 10°C. Clinical and demographic data were obtained from the electronic health record. The primary outcome was the incidence of primary graft dysfunction (PGD) grades 1 to 3 at 0, 24, 48, and 72 hours following transplantation. Secondary outcomes included duration of mechanical ventilation, length of hospitalization, length of ICU stay, postoperative extracorporeal membrane oxygenation (ECMO) requirement, and 30-day survival. Results: Among 59 lung transplants, 40 underwent extended static cold storage at 10°C and 19 underwent standard preservation. Idiopathic pulmonary fibrosis was the most common indication; 55 of 59 recipients received bilateral lung transplantation. Four cases utilized ex vivo lung perfusion (EVLP) (Lung Bioengineering Inc., Silver Spring, MD, USA). Mean ischemia times were longer in the extended group (right 573.9±237.8 vs 343.5±168.1 min; left 613.8±237.3 vs 364.1±151.2 min). There were no significant between-group differences in PGD at 0, 24, 48, or 72 hours. Length of hospitalization, mechanical ventilation duration, and ICU stay were similar. ECMO was required in 4 (10%) of extended storage cases, but none in standard preservation group. There was no difference in the incidence of PGD based on the donor type (DCD vs DBD), regardless of the extended storage at 10°C. Conclusion: Extended static lung preservation at 10 °C was not associated with a statistically significant increase in PGD or adverse short-term clinical outcomes, despite significantly prolonged ischemia times in our cohort. These findings support the feasibility of extended 10 °C preservation without compromising early post-transplant outcomes.

Indexed as

donor lung preservationextended preservation at 10°Clung transplantation

Identifiers

PMID42602443
PMCPMC13473957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.